MOLOGEN AG
Dr. Mariola Söhngen appointed as new CEO of MOLOGEN AG
MOLOGEN AG / Key word(s): Change of Personnel 23.07.2015 17:55 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad-hoc notification according to § 15 WpHG Dr. Mariola Söhngen appointed as new CEO of MOLOGEN AG Berlin, July 23, 2015. The Supervisory Board of MOLOGEN AG (ISIN DE0006637200/WKN 663720) today appointed Dr. Mariola Söhngen, co-founder of PAION AG (and Management Board member up to October 31, 2015, as Chief Medical Officer; CMO), as Member of the Executive Board and new Chief Executive Officer (CEO) of MOLOGEN AG with effect from November 1, 2015. She will be in charge of Research, Business Development, Strategy and Partnering. The presiding CEO of MOLOGEN AG, Dr. Matthias Schroff, has announced that he will resign from his post as chairman of the Executive Board on October 31, 2015 and be leaving the Executive Board with effect from December 31, 2015, by mutual agreement with the Supervisory Board. In the interim period from November 1, 2015 to December 31, 2015, Dr. Schroff will work as Executive Board member in cooperation with Dr. Söhngen to ensure a smooth transition of the chairmanship. In addition, Jörg Petraß (Chief Financial Officer; CFO) has also informed the Supervisory Board that he does not plan to extend his tenure as Executive Board Member of MOLOGEN AG, which is due to run out on December 31, 2015. However, he has offered to act as a consultant for a transitional period to enable orderly succession planning and the induction of his successor. --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: Contact Claudia Nickolaus Head of Investor Relations & Corporate Communications Tel: +49 - 30 - 84 17 88 - 38 Fax: +49 - 30 - 84 17 88 - 50 investor@mologen.com Note about risk for future predictions Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation. 23.07.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: MOLOGEN AG Fabeckstraße 30 14195 Berlin Germany Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: presse@mologen.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden